• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Fate Therapeutics, Inc. - Common Stock (NQ: FATE )

    1.680 +0.020 (+1.20%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,135,980
    Open 1.675
    Bid (Size) 1.680 (14)
    Ask (Size) 1.710 (2)
    Prev. Close 1.660
    Today's Range 1.640 - 1.800
    52wk Range 1.590 - 8.830
    Shares Outstanding 98,384,456
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -54.47%
    -54.47%
    1 Month
    -26.64%
    -26.64%
    3 Month
    -53.85%
    -53.85%
    6 Month
    -56.25%
    -56.25%
    1 Year
    -54.84%
    -54.84%

    More News

    Read More
    Fate Therapeutics Announces Leadership Transition
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
    Via Benzinga
    Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Fate Therapeutics to Present at Upcoming December Investor Conferences
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
    Via The Motley Fool
    Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
    Via Benzinga
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.